- Home
- FOF vs GOSS Comparison
FOF vs GOSS Comparison
Compare FOF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOF
- GOSS
- Stock Information
- Founded
- FOF 2006
- GOSS 2015
- Country
- FOF United States
- GOSS United States
- Employees
- FOF N/A
- GOSS N/A
- Industry
- FOF Investment Managers
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- FOF Finance
- GOSS Health Care
- Exchange
- FOF Nasdaq
- GOSS Nasdaq
- Market Cap
- FOF 354.8M
- GOSS 347.8M
- IPO Year
- FOF N/A
- GOSS 2019
- Fundamental
- Price
- FOF $13.04
- GOSS $2.47
- Analyst Decision
- FOF
- GOSS Strong Buy
- Analyst Count
- FOF 0
- GOSS 4
- Target Price
- FOF N/A
- GOSS $8.50
- AVG Volume (30 Days)
- FOF 58.7K
- GOSS 3.1M
- Earning Date
- FOF 01-01-0001
- GOSS 08-05-2025
- Dividend Yield
- FOF 9.07%
- GOSS N/A
- EPS Growth
- FOF N/A
- GOSS N/A
- EPS
- FOF N/A
- GOSS N/A
- Revenue
- FOF N/A
- GOSS $40,237,000.00
- Revenue This Year
- FOF N/A
- GOSS N/A
- Revenue Next Year
- FOF N/A
- GOSS $30.65
- P/E Ratio
- FOF N/A
- GOSS N/A
- Revenue Growth
- FOF N/A
- GOSS N/A
- 52 Week Low
- FOF $9.59
- GOSS $0.66
- 52 Week High
- FOF $11.75
- GOSS $2.65
- Technical
- Relative Strength Index (RSI)
- FOF 58.11
- GOSS 68.08
- Support Level
- FOF $13.01
- GOSS $2.38
- Resistance Level
- FOF $13.13
- GOSS $2.65
- Average True Range (ATR)
- FOF 0.09
- GOSS 0.15
- MACD
- FOF -0.01
- GOSS 0.03
- Stochastic Oscillator
- FOF 59.05
- GOSS 76.67
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.